First-of-its-kind, cloud-native AI platform for transplant program cohort analysis, clinical research, and real-world evidence generation announced at the 2026 Precision Medicine World Conference
CareDx, Inc. The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world evidence development.
VANTx is designed for secure, scalable cohort analysis across longitudinal patient timelines that enables the evaluation of treatment trends, patient outcomes, and practice patterns. The platform is intended to support clinicians, transplant programs, and pharma partners in testing hypotheses to generate actionable findings for treatment protocol development, investigator-initiated studies, and clinical trial design.
Jing Huang, Chief Data and AI Officer of CareDx, will be introducing VANTx at the Precision Medicine World Conference (PMWC) in Silicon Valley, California, on March 5, 2026, during the session “Transforming Transplant Care Through AI: From Predictive Insights to Precision Decisions.” The presentation will take place as part of the “AI in Clinical Decision Support” track.
Also Read: Take2 Raises $14 Millions to Automate Healthcare Hiring
“As the market leader in transplant precision diagnostics and patient care solutions, we can help our transplant center partners generate actionable insights using LLMs and other models.” said Jing Huang, Chief Data and AI Officer at CareDx. “I joined CareDx to lead the development of the VANTx platform and to help transplant teams and researchers make sense of complex, longitudinal data in a way that is intuitive, clinically meaningful, and actionable. I am thrilled to see this vision and the investment we have made over the past 24 months in AI architecture starting to become a reality in support of transplant care globally.”
VANTx operates on a live data pipeline of CareDx’s continuously expanding, multidimensional data repository of de-identified molecular tests and clinical trial data, with the ability to incorporate additional data at the transplant center’s request including EMR, care quality, and remote patient monitoring data. VANTx receives real‑time ingestion from laboratory and clinical data sources and is built on a Databricks environment that leverages the Llama 3 foundational model and other advanced machine-learning techniques optimized for structured clinical data. Additionally, VANTx will incorporate validated predictive and prognostic insights models from KOAR, SHORE, ALAMO, and MAPLE with the goal of supporting kidney, heart, lung, and liver transplant research, respectively. These models are intended to inform sub-analyses of predicted disease risk in areas of significant research interest to the clinical community such as delayed graft function, microvascular inflammation, antibody mediated rejection, cardiac allograft vasculopathy, and cancer risk.
VANTx is available to transplant centers through consultation with CareDx’s medical affairs team today, and the company intends to make it available through self-service permission-based access to clinicians later in 2026.
Source: Businesswire
